How WHO’s Maftivimab Priority for Bundibugyo Trials At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story

• Regeneron Pharmaceuticals recently reported that maftivimab, a key antibody in its FDA-approved Ebola therapy Inmazeb, was prioritized by the World Health Organization’s Therapeutics Advisory Group for evaluation in clinical trials targeting Bundibugyo ebolavirus amid an ongoing outbreak in Central and East Africa.
• This WHO prioritization, combined with Regeneron’s existing Inmazeb stockpiles and history of compassionate use and donations, underscores the company’s growing role in global health emergency responses.
• Next, we’ll examine how WHO’s prioritization of maftivimab for Bundibugyo ebolavirus trials may influence Regeneron’s broader investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Regeneron Pharmaceuticals Investment Narrative Recap

To own Regeneron, you have to believe its diversified biologics portfolio and R&D engine can offset pressure on mature franchises like EYLEA. The WHO’s prioritization of maftivimab reinforces Regeneron’s credibility in high impact infectious diseases, but it does not materially change the near term focus on EYLEA HD execution and the risk that higher R&D and manufacturing spend may not translate into enough new commercial wins.

Among recent updates, the FDA’s April approval of extended 20 week dosing for EYLEA HD in wAMD and DME looks far more central to the current story. That decision goes straight to the core risk around anti VEGF competition and pricing, making EYLEA HD performance a key counterweight while Ebola programs like Inmazeb and maftivimab build out Regeneron’s longer term global health profile.

Yet, while this global health progress is encouraging, investors should still pay close attention to the risk that rising R&D and manufacturing investment could...

Read the full narrative on Regeneron Pharmaceuticals (it's free!)

Regeneron Pharmaceuticals’ narrative projects $19.5 billion revenue and $6.1 billion earnings by 2029. This requires 9.4% yearly revenue growth and about a $1.7 billion earnings increase from $4.4 billion today.

Uncover how Regeneron Pharmaceuticals' forecasts yield a $875.31 fair value, a 42% upside to its current price.

Exploring Other Perspectives

Compared with the baseline worries about EYLEA and R&D productivity, the most optimistic analysts saw upside from oncology and infectious disease optionality, with bullish forecasts around US$21.0 billion revenue and US$7.7 billion earnings by 2029 that could look different once the maftivimab news is fully reflected.

Explore 8 other fair value estimates on Regeneron Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Regeneron Pharmaceuticals research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Regeneron Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Regeneron Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com